AUTHOR=Hu Chengjun , Dai Qiuxin , Zhang Ruiyi , Yang Huanping , Wang Man , Gu Kaili , Yang Jiangang , Meng Wenjun , Chen Ping , Xu Maozhong 

TITLE=Case Report: Identification of a novel LYN::LINC01900 transcript with promyelocytic phenotype and TP53 mutation in acute myeloid leukemia

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1322403

DOI=10.3389/fonc.2023.1322403

ISSN=2234-943X

ABSTRACT=<p>Acute myeloid leukemia (AML) is a malignant disease of myeloid hematopoietic stem/progenitor cells characterized by the abnormal proliferation of primitive and naive random cells in the bone marrow and peripheral blood. Acute promyelocytic leukemia (APL) is a type (AML-M3) of AML. Most patients with APL have the characteristic chromosomal translocation t(15; 17)(q22; q12), forming <italic>PML::RARA</italic> fusion. The occurrence and progression of AML are often accompanied by the emergence of gene fusions such as <italic>PML::RARA</italic>, <italic>CBFβ::MYH11</italic>, and <italic>RUNX1::RUNX1T1</italic>, among others. Gene fusions are the main molecular biological abnormalities in acute leukemia, and all fusion genes act as crucial oncogenic factors in leukemia. Herein, we report the first case of <italic>LYN::LINC01900</italic> fusion transcript in AML with a promyelocytic phenotype and <italic>TP53</italic> mutation. Further studies should address whether new protein products may result from this fusion, as well as the biological function of these new products in disease occurrence and progression.</p>